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Abstract				 The	pathogenesis	and	progression	of	many	tumors,	including	hematologic	malignancies	 is	 highly	 dependent	 on	 enhanced	 lipogenesis.	 De	 novo	 fatty-acid	synthesis	permits	accelerated	proliferation	of	tumor	cells	by	providing	structural	components	 to	 build	 the	 membranes.	 It	 may	 also	 lead	 to	 alterations	 of	physicochemical	properties	of	the	formed	membranes,	which	can	have	an	impact	on	 signaling	 or	 even	 increase	 resistance	 to	 drugs	 in	 cancer	 cells.	 Cancer	 type-specific	 lipid	 profiles	 would	 allow	 understanding	 the	 actual	 effects	 of	 lipid	changes	 and	 therefore	 could	 potentially	 serve	 as	 fingerprints	 for	 individual	tumors	 and	 be	 explored	 as	 diagnostic	 markers.	 We	 have	 used	 shotgun	 MS	approach	to	 identify	 lipid	patterns	 in	different	types	of	acute	myeloid	 leukemia	(AML)	patients	 that	 either	 show	no	 karyotype	 changes	 or	 belong	 to	 t(8;21)	 or	inv16	 types.	 The	 observed	 differences	 in	 lipidomes	 of	 t(8;21)	 and	 inv(16)	patients,	as	compared	 to	AML	patients	without	karyotype	changes,	concentrate	mostly	 on	 substantial	 modulation	 of	 ceramides/sphingolipids	 synthesis.	 Also	significant	 changes	 in	 the	 physicochemical	 properties	 of	 the	 membranes,	between	 the	 t(8;21)	 and	 the	 other	 patients,	were	 noted	 that	were	 related	 to	 a	marked	alteration	 in	 the	 saturation	 levels	of	 lipids.	The	 revealed	differences	 in	lipid	 profiles	 of	 various	 AML	 types	 increase	 our	 understanding	 of	 the	 affected	biochemical	pathways	and	can	potentially	serve	as	diagnostic	tools.				 	
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Introduction			 Acute	 Myeloid	 Leukemia	 (AML)	 is	 a	 clonal	 bone	 marrow	 disorder	resulting	 from	diverse	phenotypic	and	genetic	alterations	 in	 the	differentiation	of	 hematopoietic	 stem	 cells	 causing	 excessive	 proliferation,	 growth	 and	accumulation	 of	 abnormal	 immature	 leukemic	 neoplastic	 cells,	 called	 blasts1-4.	The	 major	 causes	 of	 AML	 are	 deregulations	 in	 one	 or	 more	 of	 the	 numerous	components	of	the	signaling	networks	that	control	cell	growth	and	proliferation,	either	 by	 a	 gain-of-function	 mutations	 or	 their	 overexpression5,6.	 Most	 efforts	towards	molecular	characterization	of	AML	have	been	directed	towards	changes	in	 the	 genome,	 transcriptome	or	proteome	 7-12,	while	 it	 becomes	more	 evident	that	pathogenesis	and	progression	of	cancer	not	only	involves	changes	in	cellular	lipidomes	 but	might	 even	 be	 accelerated	 by	 these13-19.	 In	 fact,	 the	 hallmark	 of	many	 tumors,	 including	 hematologic	 malignancies	 is	 enhanced	 lipogenesis,	arising	 from	 increased	activities	of	 fatty	acid	biosynthetic	enzymes	 (Acc1,	Fasn	and	 Scd1)20-23.	 Accelerated	 fatty	 acid	 synthesis	 may	 permit	 faster	 growth	 of	tumor	 cells.	 Furthermore,	 synthesis	 of	 monounsaturated	 fatty	 acids	 may	 have	additional	 benefits	 as	 it	 has	 been	 shown	 that	 oleate	 can	 protect	 cells	 against	saturated	fatty	acid	toxicity	and	cellular	stress18,22,24,25.	Acc1,	Fasn	and	Scd1	have	therefore	been	identified	as	plausible	targets	for	cancer	therapy14,18,20-23.			One	of	the	 lipid	 classes,	 which	 has	 been	 associated	 with	 cancer	 pathogenesis	 are	sphingolipid	 metabolites	 like	 ceramides,	 lactosylceramide	 and	 sphingosine-1-phosphate,	which	act	as	effector	molecules15.	Ceramide	in	particular	is	intimately	involved	in	the	regulation	of	cancer-cell	growth,	differentiation,	senescence	and	apoptosis26-28.	 Attenuation	 of	 ceramide	 levels	 by	 its	 conversion	 to	glucosylceramide	 contributes	 to	 the	 multidrug	 resistance	 of	 several	 human	cancer	 types,	 including	 leukemia,	 breast	 cancer,	 melanoma	 and	neuroblastoma17,29-31.	Moreover,	 sphingolipids	 are	 a	 family	 of	membrane	 lipids	with	 important	 structural	 roles	 in	 the	 regulation	of	 the	 fluidity	and	subdomain	structure	of	 the	 lipid	bilayer,	 especially	 lipid	 rafts32.	These	nanodomains	act	as	regulatory	 platforms	 for	 a	 number	 of	 growth	 factor	 receptors	 e.g.	 EGFR,	 c-kit,	VEGFR	 etc.	 controlling	 the	 initiation	 of	 signaling	 cascades	 that	 regulate	 cell	growth	 and	 differentiation33,34.	 Therefore,	 deregulation	 of	 lipid	 metabolism	
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might	 in	 consequence	 lead	 to	 perturbations	 in	 domain	 structures	 within	 the	cellular	 membranes.	 Until	 today	 regulatory	 mechanisms	 that	 govern	 lipid	metabolism	 and	 homeostasis	 are	 largely	 unknown.	 The	 metabolic	 network	 of	enzymes	 and	 factors	 that	 regulates	 the	 enormous	heterogeneity	 of	 the	distinct	lipid	species	is	poorly	understood.	Notably,	metabolic	transitions	that	affect	lipid	metabolism	 are	 prone	 to	 induce	 lipidome-wide	 ripple	 effects	 and	 prompt	compensatory	metabolic	responses35,36.	Therefore	there	is	a	growing	interest	in	understanding	the	effects	of	lipid	changes	in	order	to	uncover	lipid	profiles	that	could	 potentially	 serve	 as	 a	 unique	 cellular	 fingerprint	 for	 individuals	 and	 be	explored	as	diagnostic	markers.		The	purpose	of	 this	study	was	to	explore	whether	 lipidomics	can	be	 integrated	into	 clinical	 research	 by	 characterizing	 the	 lipidomic	 profiles	 of	 AML	 patients.	We	have	focused	on	three	subsets	of	patients	with	specific	clinical	and	biological	AML	 characteristics:	 translocation	 t(8;21),	 inversion	 inv16	 and	 patients	 with	normal	 karyotype	 (AML-nk).	 Chromosomal	 abnormalities	 are	 detected	 in	approximately	 60%	 of	 newly	 diagnosed	 AML	 patients	 among	 which	 the	 most	common	 are	 t(8;21)	 and	 inv16	 that	 affect	 the	 expression	 of	 the	 Core	 Binding	Factor	 (CBF),	 a	 heterodimeric	 transcription	 factor	 controlling	 key	 programs	 in	cell	 survival37-39	 ,	 at	 least	 in	 part,	 through	 regulating	 sphingolipid	metabolism	40,41.	 The	 t(8;21)	 and	 inv16	 are	 usually	 associated	 with	 good	 prognosis	 and	survival.	 The	 ‘normal	 karyotype’	 AML	 group	 is	 very	 heterogeneous	 as	 it	emanates	 from	a	number	of	 factors	that	consist	of	aberrant	signal	transduction	pathways	 and	 cause	 uncontrolled	 growth	 and	 inhibition	 of	 apoptosis2,6,42.	Moreover,	 these	 changes	 are	 often	 associated	 also	 with	 increased	 activity	 of	multidrug	resistance	proteins	and	renewal	of	leukemia	stem	cells30,31.		We	 applied	 shotgun	 mass	 spectrometry	 approach	 to	 analyze	 the	 cellular	lipidomes	 of	 the	 various	 AML	 types	 and	we	 could	 identify	marked	 differences	among	the	various	AML	types.	The	observed	lipid	patterns	can	therefore	be	used	to	identify	metabolic	pathways	targeted	in	personalized	anti-cancer	therapies.		 	
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Materials	and	Methods		
Leukocytes	collection		t(8;21),	 inv16	 and	 normal	 karyotype	 (AML-nk)	 AML	 samples	 were	 collected	from	patients	at	 the	 time	of	diagnosis,	 so	before	any	AML	specific	 therapy	was	applied.	The	samples,	and	were	stored	as	cryopreserved	stocks.	Full	description	of	patients	can	be	found	in	Table1.			
Lipids	and	lipid	standards			Synthetic	 lipid	 standards:	 cholesterol	 (Chol-d6)	 (deuterated),	 sterol	 ester	 (CE	20:0),	 triacylglycerol	 (TAG	 17:0-17:0-17:0),	 diacylglycerols	 (DAG	 17:0-17:0),	phosphatidic	 acid	 (PA	 17:0-17:0),	 phosphatidylcholine	 (PC	 17:0-17:0),	phosphatidylethanolamine	(PE	17:0-17:0),	phosphatidylglycerol	(PG	17:0-17:0),	phosphatidylserines	 (PS	 17:0-17:0),	 phosphatidylinositol	 (PI	 16:0-16:0),	lysoglycerophospholipids	 (LPA	 17:0,	 LPC	 12:0,	 LPE	 17:1,	 LPS	 17:1,	 LPI	 17:1),	sphingomyelin	(SM	18:1;2-12:0)	and	ceramides	(Cer	18:1;2-17:0,	GlcCer	18:1;2-12:0,	 LacCer	 18:1;2-12:0)	 were	 purchased	 from	 Avanti	 Polar	 Lipids.	 Total	protein	 concentration	 of	 leukemic	 cells	 was	 estimated	 using	 the	 microBCA	Protein	Assay	Kit	(Thermo	Scientific).	Aliquots	of	cells	equivalent	to	20-25ug	of	protein	 that	 correspond	 to	 ~250	 000	 cells,	 were	 transferred	 into	 2ml	 tubes	(Eppendorf	 AG),	 pelleted	 (1000g,	 5’)	 washed	 twice	 in	 1000µl	 of	 155mM	ammonium	 bicarbonate	 and	 were	 spiked	 with	 10µl	 mixture	 of	 internal	 lipid	standards	 dissolved	 in	methanol.	 All	 samples	were	 subjected	 to	 two-step	 lipid	extraction	with	750µl	of	10:1	chloroform:methanol	(C/M)	(v/v)	followed	by	2:1	C/M	mixture	at	4oC,	respectively.	The	lipid	extracts	were	collected	from	organic	phases	 and	 evaporated	 under	 vacuum.	 Dry	 lipid	 extracts	 were	 re-dissolved	 in	100µl	 of	 chloroform/methanol	 1:2	 (v/v)	 and	 analyzed	 on	 Q-Exactive	 (Thermo	Fisher	 Scientific)	 instrument	 equipped	 with	 electrospray	 ion	 source	 -	 ESI	TriVersa	Nanomate	(Advion	Biosciences).	Three	independent	runs	were	done	for	each	lipid	extract.		
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Shotgun	Lipidomics	Analysis	and	Data	Processing		Lipid	 extracts	 (7.5µl)	 from	 the	 first	 extraction	 step	 were	 diluted	 in	 13mM	ammonium	acetate	in	propanol	(10µl)	to	achieve	the	final	solvent	composition	of	7.5mM	ammonium	acetate	 in	chloroform/methanol/propanol	1:2:4	(v/v).	Lipid	extracts	 from	 the	 second	 extraction	 step	 were	 dissolved	 in	 10µl	 of	 0.01%	methylamine	 as	 an	 ion	 modifier	 and	 subjected	 to	 negative	 mode	 MS	 analysis.	Lipid	extracts	from	10:1	organic	phase	were	analyzed	with	polarity	switching	in	both	positive	and	negative	 ion	mode,	 the	2:1	extracts	 in	negative	only.	Positive	ion	mode	analysis	was	performed	using	FTMS	with	target	resolution	of	280,000	at	m/z	 200	 and	MS/MS	with	 17,500	 at	m/z	 200	 to	monitor	 CE,	DAG	 and	TAG	species.	Negative	 FTMS	mode	was	 chosen	 to	monitor	 lyso-phospholipids	 (LPG,	LPS,	 LPI,	 LPS,	 LPC,	 LPE)	 and	 combined	 with	 tandem	 MS/MS	 for	 selected	phospholipids	(PC,	PC	O-,	PE,	PE	O-,	PS,	PA,	PI,	PG),	sphingolipids	(SM,	Cer,	Hex-Cer,	 diHex-Cer)	 globosides	 (Gb3	 and	 Gb4)	 and	 ganglioside	 GM3.	 The	 same,	targeted	 resolution	 settings	 were	 used	 for	 both	 polarities.	 Cholesterol	 was	measured	 separately	 after	 chemical	 acetylation43.	 Briefly,	 20µl	 of	 10:1	 lipid	extract	was	dried	down	and	75µl	of	acetyl	chloride	in	1:2	C/M	(v/v)	added.	After	an	hour	incubation	samples	were	dried	down,	re-dissolved	in	50µl	C/M	1:2	and	analyzed	 in	positive	 ion	mode,	using	similar	settings	as	described	above.	Molar	amounts	of	 lipid	species	were	determined	using	spiked-in	 internal	quantitative	standards.	Samples	were	 infused	 into	 the	Q-Exactive	 instrument	with	TriVersa	NanoMate	ESI	source.	Data	acquisition	was	performed	in	both	positive	and	negative	mode	with	 polarity	 switching	where	MS	was	 used	 for	 quantification	 and	MS/MS	 for	fatty	 acids	 and	 lipid	 precursors	 identification.	 Data	 were	 analyzed	 and	 de-convoluted	 by	 LipidXplorer	 software.	 Data	 visualization	 and	 normalization	(pmol,	mol%)	calculations	were	performed	 in	Microsoft	Excel,	GraphPad	Prism	6.0	and	SIMCA	14.0	software.		
GP	measurements		For	 fluidity	 analysis,	 dried	 lipids	 were	 rehydrated	 in	 150	 mM	 NaCl,	 25	 mM	HEPES	 pH	 7.25.	 The	 resulting	 liposomes	 were	 subsequently	 subjected	 to	 10	
	 7	
freezing/thawing	 cycles	 (liquid	 nitrogen/37°C)	 and	 extruded	 through	 100nm	polycarbonate	 filters.	 Finally,	 vesicles	 were	 stained	 (15	 min)	 with	 2	 μM	 C-laurdan.	 Fluorescence	 emission	 spectra	were	 recorded	 (Ex.	 385	 nm,	 Em.	 400–550	nm)	and	analyzed	as	described	in	Kaiser	et	al.44		
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RESULTS		
Lipidome	analysis	reveals	significant	differences	among	the	AML	subtypes		 Total	 leukocyte	 fractions	 containing	 250	 000	 cells,	 corresponding	 to	approximately	20-25µg	of	total	protein	content,	were	subjected	to	two-step	lipid	extraction	 and	 used	 for	 MS	 lipidomics	 measurements	 and	 GP	 measurements.	Shotgun	 lipidomics	MS	 and	MS/MS	 designed	 acquisition	 routine	 together	with	in-house	developed	lipidomics	software	enabled	to	profile	more	than	400	unique	lipid	species	of	the	25	analyzed	lipid	classes.			 To	 gain	 a	 better	 understanding	 of	 the	 observed	 variations	 among	 the	lipidomes,	 multivariate	 statistical	 data	 analysis	 was	 applied.	 For	 dimension	reduction	and	visualization	of	the	data,	we	have	performed	Principal	Component	Analysis	with	 Pareto	 scaling	 in	 SIMCA	 software.	 This	 statistical	 tool	 is	 used	 to	emphasize	variation	and	bring	out	strong	patterns	in	a	dataset.	PCA	was	applied	to	 lipidomics	 data	 that	 were	 first	 normalized	 to	 the	 internal	 standards	 and	transformed	 to	 mol%	 values.	 Subsequently	 two-dimensional	 score	 plot	 was	generated	 (R2X	values	were	0.253	and	0.094	 for	 the	 first	and	second	principal	components,	 respectively)	 (Figure	1),	which	showed	that	 t(8;21)	samples	were	clearly	separated	from	the	inv16	and	AML-nk	patient	samples,	that	were	mixed	within	one	cluster.	This	suggested	that	we	should	expect	substantial	differences	between	the	lipidomes	of	t(8;21)	and	the	other	AML	types.					 To	check	if	the	lipidome	differences	are	significant	we	have	compared	the	lipidomes	of	different	AML	types	among	each	other	using	the	orthogonal	partial	least	 square-	 discriminant	 analysis.	 In	 all	 cases,	 the	 differences	 appeared	significant	(p<0.01),	also	 in	 the	case	of	 inv16	and	AML-nk	that	 formed	a	mixed	cluster	in	the	PCA	plot.	Next,	the	actual	differences	in	lipid	species	were	analyzed	by	comparing	the	various	AML	types	among	each	other.	Briefly,	lipid	fold	change	followed	 by	 multiple	 t	 tests	 analysis	 was	 calculated,	 which	 allowed	 the	identification	of	unique	species	with	the	most	pronounced	difference	(Figure	2).	The	 major	 difference	 between	 the	 t(8;21)	 and	 AML-nk	 was	 observed	 for	
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ceramide	 backbone-containing	 lipids:	 SM,	 Cer,	 Hex-Cer	 and	 GM3	 ganglioside	(Figure	 2A).	 Decrease	 of	 SM	 in	 t(8;21)	was	 correlated	with	 an	 increase	 in	 the	levels	of	ceramides	(up	to	3-fold),	Hex-Cer	(up	to	5-fold)	and	GM3	(up	to	15-fold)	suggesting	a	shift	towards	synthesis	of	glycosphingolipids.	Unfortunately	it	is	not	clear	 if	 GM3	 derivatives,	 bearing	 additional	 sugar	 modifications,	 are	 also	upregulated	 since	 these	 cannot	 be	 currently	 measured	 quantitatively	 with	shotgun	MS	technique.	When	we	compared	the	t(8;21)	and	inv16	groups	to	each	other	(Figure	2B),	we	also	observed	mostly	changes	in	the	expression	profiles	of	lipids	 belonging	 to	 the	 sphingolipid	 pathways.	We	 observed	 a	 decrease	 in	 the	levels	 of	 SM	and	 an	 increase	 in	 the	 synthesis	 of	 the	 glycosphingolipids	 (Figure	2C).	 Interestingly	 the	 t(8;21)	 seem	also	 to	 contain	more	 ceramides	 than	 inv16,	suggesting	that	this	type	of	leukemic	cells	might	be	more	prone	to	apoptosis26-28.	The	 inv16	 and	 AML-nk	 patients	 represent	 a	mixed	 population	 in	 the	 PCA	 plot	(Figure	 1).	Nevertheless,	 direct	 comparison	 of	 these	 two	 groups	 also	 points	 to	noticeable	 lipidome	 differences	 (p<0.001)	 (Figure	 2c).	 The	 most	 prominent	change	was	the	increased	abundance	of	various	species	of	Hex-Cer	in	the	inv16	samples.	These	lipids	are	the	precursors	for	production	of	other	glycolipids,	but	they	 have	 been	 also	 suggested	 to	 play	 an	 important	 role	 in	 multidrug	resistance17,29,31.	 It	 seems	 like	 we	 observed	 a	 specific	 accumulation	 of	 this	particular	 lipid	 class,	 rather	 than	 a	 shift	 in	 glycosphingolipid	 metabolism,	 as	observed	for	the	t(8;21)	cells.			
Measurement	of	Generalized	Polarization	Index	reveal	dramatic	changes	in	
membrane	fluidity	in	t(8;21)	cells.				 Activation	of	the	lipogenic	pathway	at	early	stages	of	cancer	pathogenesis	is	 critical	 for	 proliferation	 of	 various	 types	 of	 tumors	 including	 hematologic	malignancies21,23.	 The	majority	 of	 newly	 synthesized	 fatty	 acids	 in	 cancer	 cells	are	 converted	 predominantly	 to	 membrane	 phospholipids.	 Specifically,	 the	proportion	 of	 monounsaturated	 and	 polyunsaturated	 fatty	 acids	 in	 the	 major	phospholipids	 was	 reported	 to	 be	 significantly	 higher	 in	 cancer	 compared	 to	noncancerous	tissues45.	Here	we	compared	each	type	of	leukemia	to	see	if	there	are	important	differences	in	saturation	levels	of	lipids.	A	marked	difference	was	
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observed,	 especially	 in	 case	 of	 the	 t(8;21)	 leukemia,	 where	 a	 significant	 shift	towards	polyunsaturated	 fatty	acids	at	 the	cost	of	monounsaturated	was	noted	(Figure	3A).	 This	was	however,	 clearly	 observed	only	 for	 the	membrane	 lipids	(phospholipids+sphingolipids),	which	 consist	 roughly	 80%	of	 all	 the	measured	lipids,	 but	 not	 for	 the	 group	 of	 storage	 lipids	 (TAG,	 DAG,	 SE)	 (Supplementary	Figure	 1).	 Alterations	 in	 fatty	 acid	 saturation	 can	 dramatically	 influence	membrane	 properties	 and	 in	 consequence	 affect	 many	 aspects	 of	 the	 cellular	machinery.	 Higher	 level	 of	 unsaturation	 may	 result	 in	 higher	 cell	 growth	 and	proliferation	 or	 protection	 from	 ER	 stress.	 On	 the	 other	 hand	 it	 has	 been	reported	 that	 the	 shift	 towards	 increased	 levels	 of	 saturated	 and	monounsaturated	phospholipids,	potentially	protects	cancer	cells	from	oxidative	damage	by	reducing	lipid	peroxidation14,18.	Fatty	 acid	 saturation	 and	 length	 or	 cholesterol	 content	 are	 the	 3	 major	components	influencing	membrane	fluidity.	Since	we	observed	a	significant	shift	of	 fatty	 acid	 saturation	 and	 we	 did	 not	 observe	 major	 changes	 in	 cholesterol	abundance	 or	 fatty	 acid	 length	 (Figure	 3	 and	 Supplementary	 Figure	 1)	 we	speculated	 that	 there	 should	 be	 substantial	 change	 in	 membrane	 fluidity	between	 t(8;21)	 and	 the	 other	 AML	 types.	 To	 validate	 our	 data,	 we	 have	prepared	small	unilamellar	vesicles	 from	the	extracted	 lipids	and	we	measured	membrane	fluidity	(General	Polarization	Index,	GP)	using	c-laurdan	as	described	elsewehere46.	 Indeed,	 a	 tight	 correlation	 between	 the	 measured	 levels	 of	unsaturation	 and	 GP	 values	 was	 obtained,	 confirming	 that	 t(8;21)	 samples	contain	 more	 fluid	 membranes.	 These	 findings	 underline	 the	 importance	 of	precise	measurements	of	lipid	and	desaturation	levels	in	cancer	cells	in	order	to	understand	which	metabolic	 pathways	 are	 aberrantly	 regulated	 and	 therefore	could	be	potential	targets	for	therapy.						 	
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Discussion			 Similar	to	embryonic	cells,	cancer	cells	are	highly	dependent	on	de	novo	lipogenesis	 for	 their	 proliferation,	 and	 the	 lipogenic	 pathway	 is	 activated	 at	 a	relatively	early	stage	in	various	types	of	tumors18,21,47.	Moreover,	there	seems	to	be	 a	 correlation	 between	 fatty	 acid	 synthase	 expression,	 which	 is	 highly	increased	in	metastatic	tumors,	increased	membrane	fluidity	and	the	decreased	patient	survival48-51.	The	majority	of	newly	synthesized	fatty	acids	in	cancer	cells	are	converted	predominantly	to	phospholipids,	which	are	then	incorporated	into	membranes	 of	 proliferating	 cancer	 cells18.	 Changes	 in	 lipid	 metabolism	disturbing	equilibrium	among	the	saturation	levels	of	fatty	acids	incorporated	in	the	membrane	lipids	might	lead	to	changes	in	membrane	fluidity	and	affect	the	structure	and	composition	of	membrane	domains	(rafts)	from	which	many	of	the	important	 signaling	 cascades	 originate.	 In	 consequence	 aberrant	 signal	transduction	 might	 enhance	 the	 proliferation	 and	 survival	 of	 hematopoietic	progenitor	cells2,6.	Additional	layer	of	complexity	arises	as	a	consequence	of	the	metabolic	interconversions	of	one	lipid	to	another	—	e.g.	conversion	of	PI(4,5)P2	to	DAG	or	DAG/PC	to	PA,	which	again	may	have	pronounced	effect	on	signaling	events52,53.	Similarly	many	sphingolipid-regulated	functions	have	significant	and	specific	links	to	various	aspects	of	cancer	initiation,	progression	and	response	to	anticancer	 treatments	 e.g.	 hydrolysis	 of	 ceramide	 produces	 sphingosine,	 the	phosphorylation	 of	 which	 yields	 sphingosine-1-phosphate	 that	 regulates	 cell	growth	and	suppresses	programmed	cell	death54-56.	As	such,	the	many	pathways	of	sphingolipid	metabolism	constitute	an	 interconnected	network	 that	not	only	regulates	 the	 levels	 of	 individual	 biologically	 active	 molecules,	 but	 also	 their	interconversion	and,	ultimately,	the	balance	among	them.	Thus	the	difference	in	lipid	 metabolism	 between	 tumors	 and	 normal	 tissues	 renders	 the	 lipogenic	pathway	an	attractive	target	for	anti-cancer	therapies,	which	so	far	was	exploited	moderately,	at	best23,57.			 It	 should	 be	 noted	 that	 in	 both	 t(8;21)	 and	 inv16	 AML	 types,	 due	 to	karyotype	 changes,	 deregulation	 of	 CBF	 expression	 occurs	 and	 it	 has	 been	reported	 previously	 that	 CBF	 controls	 the	 expression	 of	 some	 of	 the	 genes	involved	 in	sphingolipid	metabolism40,41.	 Its	overexpression	has	been	shown	to	
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reduce	 intracellular	 long-chain	 ceramides	 in	NIH3T3	 fibroblasts	 and	 to	 elevate	extracellular	 sphingosine-1-phosphate	 levels40.	 On	 the	 other	 hand,	 in	 CBFβ-silenced	 cells	 substantial	 increases	 in	 ceramide	 species	 and	 decreases	 in	lactosylceramides	were	identified	that	correlated	with	enhanced	cell	death41.		 Here	for	the	first	time	we	show	and	quantify	the	changes	in	the	lipidomes	of	these	cells.	Indeed	the	major	differences	discovered	between	the	various	AML	types	 consist	 of	 changes	 in	 the	 sphingolipids	 and	 ceramides.	 Interestingly,	although	 both	 t(8;21)	 and	 inv16	 share	 similarities	 in	 genetic	 background	(deregulation	of	CBF	expression),	 there	are	still	significant	differences	between	their	 sphingolipid	metabolism.	The	 t(8;21),	 as	 compared	 to	 inv16	and	AML-nk,	shows	 substantial	 decrease	 of	 sphingomyelin,	 probably	 a	 result	 of	 decreased	expression	 of	 SGMS1	 and	 SGMS2	 genes7,	 which	 detours	 ceramides	 to	glycosphingolipids	 synthesis	 pathway.	 In	 inv16	 samples	 the	 sphingolipid	metabolism	 looks	much	more	 equilibrated	 and	 only	 a	 specific	 accumulation	 of	hexosylceramides	 is	 observed	 (Figure	 2C),	 which	 has	 been	 reported	 as	 a	multidrug	 resistance	 phenotype	 in	 many	 cancer	 cells17,29-31.	 The	 observed	pattern	 is	 particularly	 interesting	 as	 in	 t(8;21)	 and	 inv16	 patients	 sensitive	 to	ABT737	(Bcl-2	inhibitor)	and	BV6	(antagonist	of	inhibitor	of	apoptosis	proteins)	drugs,	genes	responsible	for	ceramide	synthesis	were	upregulated	in	contrast	to	patients	 resistant	 to	 these	 drugs7.	 Changes	 in	 expression	 of	 enzymes	 of	sphingolipid	 metabolism	 in	 several	 cancers	 are	 consistent	 with	 the	 emerging	tumor-suppressor	 functions	 of	 ceramide.	 Our	 data	 provide	 evidence	 that	ceramide	 levels	 significantly	 differ	 among	 various	patients,	 even	 those	 bearing	similar	genetic	perturbations,	which	might	directly	correlate	with	susceptibility	of	these	patients	to	chemotherapy.			 Among	all	studied	groups,	the	t(8;21)	patients	display	highest	membrane	fluidity,	which	must	be	 the	effect	of	 an	 increased	unsaturation	 level	within	 the	fatty	 acid	 moieties	 of	 the	 membrane	 lipids.	 Increased	 membrane	 fluidity	 has	been	associated	with	increased	cell	growth	and	proliferation	in	many	cancers58-60.	 It	 has	 been	 also	 previously	 shown	 to	 modulate	 certain	 receptor	 tyrosine	kinase	proteins,	resulting	in	disturbed	signaling61-64.	In	line	with	this,	some	drugs	are	membrane	active,	and	it	has	been	suggested	that	the	ability	of	a	drug	to	alter	a	membrane	fluidity	correlates	with	the	drug	activity65,66. 	
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	 AML	with	 its	mosaic	etiological	 factors	necessitates	a	systemic	approach	for	 mechanistic	 understanding	 and	 for	 optimization	 of	 therapeutical	 targets.	Lipid	 signatures	 quantified	 here	 correlated	 with	 cytogenetic	 abnormalities	 of	leukemic	cells,	which	paves	the	way	towards	new	diagnostics	and	could	offer	a	prognostic	value	for	clinical	patient	evaluation.		
	
	
Conclusion		 Mass	 spectrometry-driven	 quantitative	 analysis	 of	 cellular	 lipids,	especially	 the	 so-called	 shotgun	 lipidomics	 technique	 is	 increasingly	 being	explored	 for	 its	 potential	 as	 a	 clinical	 diagnostic	 tool.	 A	 major	 benefit	 of	 this	technology	 is	 that	 hundreds	 of	 lipid	 species	 can	 be	 directly	 identified	 and	accurately	 quantified	 in	 a	 relatively	 short	 analysis	 time67-69.	 This	 work	demonstrates	that	a	lipidomic	analysis	of	acute	myeloid	leukemia	cells	could	be	employed	 for	 stratification	 of	 hematological	 malignancies.	 The	 observed	imbalances	 of	 lipid	 synthesis	 pathways	 might	 directly	 contribute	 to	 disease	progression.						
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Figure	1.	Score	plots	of	the	multivariate	analysis	by	PCA.	The	t(8;21)	samples	are	separated	from	the	inv16	and	AML-nk	samples.	Each	patient	sample	was	measured	in	triplicates	and	each	point	on	 the	 plot	 represents	 an	 individual	 measurement.	 The	 calculated	 R2X	 values	 are	 0.253	 and	0.094	for	the	first	and	second	component,	respectively.	The	analysis	was	performed	using	SIMCA	14.0	software.			
	
Figure	 2.	 Lipidomic	 analysis	 of	 AML	 samples.	 Volcano	 plots	were	 obtained	 from	 comparative	analysis	 of	 3	 different	 AML	 types.	 Each	 point	 on	 the	 graph	 represents	 single	 lipid	 specie.	 The	analysis	was	performed	using	SIMCA	14.0	software.		
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Figure	3.	Lipid	features	extracted	from	AML	samples.	(A)	Saturation	index	of	all	lipids	measured	with	 shotgun	MS.	 The	 analysis	 revealed	 significant	 changes	 of	 the	mono-	 and	 polyunsaturated	fatty	acids	in	t(8;21)	samples.		(B)	GP	index	of	liposomes	prepared	from	lipid	extracts	of	various	AML	samples.	GP	is	a	relative	indicator	of	the	membrane	order	(higher	GP	equals	more	ordered	membranes).	t(8;21)	samples	show	lower	GP	values,	which	means	that	their	membranes	display	higher	fluidity.		
	
Supplementary	 Figure	 1	 –	 Lipid	 features	 (fatty	 acid	 saturation	 and	 length)	 measured	 with	shotgun	MS	of	the	membrane	(PC,	PC-O,	PE,	PE-O,	PS,	PI,	PG,	PA,	SM,	Cer,	HexCer,	DiHexCer,	GM3,	Gb3,	Gb4)	and	storage	lipids	(SE,	TAG,	DAG).			
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Table	1.	Description	of	patients.			
ID karyotype sex age 
FLT3-
ITD 
mutation 
FLT3-ITD 
ratio 
NPM1 
mutation 
KIT 
mutation 
first complete 
remission 
achieved  
relapse after 
complete 
remission 
1 normal f 81 N  Y NA N N 
2 normal m 59 Y 0.92 Y NA Y Y 
3 normal f 62 Y 0.91 Y NA N N 
4 normal f 72 Y 5.9 Y NA N N 
5 normal f 72 N  Y NA Y Y 
6 normal m 63 Y NA Y NA Y N 
7 inv16 f 53 N  N N N N 
8 inv16 f 30 N  N N Y Y 
9 inv16 m 28 N  N Exon 8 Y Y 
10 inv16 m 36 N  N Exon 8 Y N 
11 inv16 m 41 N  N N Y Y 
12 t(8;21) m 37 N  N N Y N 
13 t(8;21) f 26 N  N D816V/H Y N 
14 t(8;21) m 41 N  N N Y N 
15 t(8;21) m 53 N  N D816V Y N 
16 t(8;21) f 34 N    N N Y Y 		f-	female;	m-male;	NA-no	information;	N-no;	Y-yes;					 		
